Article Details
Retrieved on: 2025-04-11 18:47:36
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses biotech firm Nektar Therapeutics, focusing on its stock upgrade by Jefferies due to promising Rezpeg trials for autoimmune diseases like atopic dermatitis and alopecia areata. The financial maneuvers and varying analyst opinions are also noted.
Article found on: www.tradingview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here